ASX expected to edge higher, despite mixed leads from overseas markets

Published 05-MAY-2020 09:20 A.M.

|

2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

The S&P/ASX 200 (XJO) had a rocky ride on Monday, continuing its downward trend from Friday’s fallout in morning trading before staging a comeback to finish up 74 points or 1.4% to 5319 points.

We mentioned yesterday that building approvals for March would be released, and that this information could impact companies that provide services to the construction sector.

While new housing approvals fell 4%, this was better than expected.

However, a number of stocks exposed to the building industry took a hit, arguably because investors anticipate that March data is the thin edge of the wedge with things set to worsen in the coming months.

There were mixed leads from overseas with the FTSE 100 down slightly, while sharp falls were recorded in Germany and France.

The US was also a mixed bag with the Dow just edging into positive territory in the last hour, while the NASDAQ posted a 105 point gain.

The SPI200 indicates the ASX could see another positive day, up 17 points to 5335 points.

24 hours

Looking across the time zones, Australia fared much better than Asian markets where the Hang Seng was hit hard, tumbling 1030 points or 4.2% to close at 23,613 points.

The Nikkei 225 shed 2.8% or 574 points, closing at 19,619 points.

The Shanghai Composite bucked the trend, increasing 1.3% to 2860 points.

The UK market opened sharply lower with the FTSE 100 slumping to about 5700 points before finishing the day at 5754 points, down 0.2%.

However, the real carnage was in mainland Europe with the CAC 40 plunging 194 points or 4.2% to close at 4378 points.

The DAX didn’t fare much better, shedding nearly 400 points or 3.6% to close at 10,467 points.

While the Dow spent most of the day in negative territory, hitting a low of 23,361 points, a late rally saw it close at 23,750 points, a gain of 0.1%.

The S&P 500 was up 0.4% to 2842 points.

However, the NASDAQ was the star performer, led higher by strong performances across the tech sector as it gained 105 points or 1.2% to close at 8710 points.

As US markets staged their late rally the CBOE Volatility Index started its decline, finishing down 3.3% at 36 points.

On the commodities front, Brent Crude rallied 3.1% to US$27.26 per barrel driving strong gains in the likes of ExxonMobil and Chevron.

There was little movement in the gold price as it continued to fluctuate between about US$1700 per ounce and US$1725 per ounce.

The Australian dollar is fetching just over US$0.64.

The RBA will be releasing its monetary policy decision at 2:30 PM today with analysts generally of the view that the cash rate will remain unchanged.

However, the rhetoric accompanying the RBA’s statement will be closely examined to gain an idea of what may play out in the coming months.

This being the case, there could be some volatility in the Australian dollar.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X